EVERSANA

Apply Today! Supply Chain Transportation Director: https://smrtr.io/mphVr | Transportation Analyst: https://smrtr.io/mphWc Our #SupplyChain team is growing! Headquartered in downtown #Memphis, our #ChannelManagement team excels in client delight, data and analytics, and camaraderie. Take the next step in your #career and do work that matters. #Hiring #Job

Impactfully navigating the rise of Integrated Delivery Networks (IDNs) requires manufacturers to implement complex decision-making strategies with multiple stakeholders beyond just prescribers. Field teams need to engage a diverse range of stakeholders within IDN systems, ensuring prescribers are well-informed about new and existing therapies. Learn more in this new article from Gregory Skalicky, MBA, KRISTA PINTO and Faruk Abdullah as they expound how this comprehensive approach supports informed decisions that enhance #patientcare and streamline #healthcaredelivery Read now: https://lnkd.in/ggjtuqbr

Attending #NACDSTSE? Connect with our experts: https://ow.ly/z9yN50SFcS8 Discover how EVERSANA is disrupting industry standards, distributing over 330 million units and launching 600 products annually, with 99.6% accuracy.

Learn more: https://ow.ly/b7Ij50SFy6F Discover how biotech enterprises can navigate the complex landscape of global commercialization. Learn from industry leader Kyle Jenne’s insights on orchestrating successful global launches. #Biotech #GlobalLaunch #Commercialization

Read the blog: https://ow.ly/Ju5i50SKqPo NICE has just updated its Real-World Evidence (RWE) Framework to enhance the quality and transparency of evidence. The new framework includes guidance on external validity bias and the transportability of international data. 🌍 At EVERSANA, we are committed to leveraging these advancements to drive impactful healthcare solutions. Learn more about how we can support your RWE needs. Chris Cameron, Deepika Thakur, Pamela V. #Healthcare #RWE #NICE #EVERSANA #Innovation

Read now: https://ow.ly/vo0g50SkgOE Pharmaceutical manufacturers must be informed about the risks and opportunities associated with the FDA guidance on scientific information on unapproved uses (SIUU), especially when launching independently. In this article, our experts help distill the draft guidance into top-level considerations to help companies understand its potential implications and prepare commercialization strategies that balance business impact with scientific integrity, compliance and patient well-being.

Read the blog: https://lnkd.in/g7gCePw7 Explore the cutting-edge methods used by Stefanie Paganelli, Tim Disher, Jenna Ellis, and Imtiaz Samjoo from EVERSANA’s Value & Evidence team to enhance clinical decision-making in #mCRPC treatment. Their application of the Daniels and Hughes Surrogate Model fills critical data gaps, enabling comprehensive network meta-analyses. Learn more about their impactful work in our latest blog post.

At EVERSANA, we believe that #ProfessionalDevelopment never ends, especially for our executives. So, in January we started our first #Leadership Excellence Program. Please join us in congratulating our first cohort! Tracy A., Penny Bemus, Patrick Brodfuehrer, Heather Cameron, Heather Christensen, Christina Christos, Michael DeLuca, PharmD, MBA, MSRA, Maria Eckley (She/Her), Sophie Ferronato, Chad Gibson, Mike Gordon, Adam Hardy PhD, Tylor Hermanson, Christina Hillestad, Chris Lagoeiro, Tony Malik, Sybil Mead, Amy Merchant, Christina Sanford Paulson, Katelyn Ray, Jane Richter, Jason Romano, Saryn Sands, Anthony Scatamacchia, Sohel Shameem, Justin Stenz, MBA, Dr. Mahendra Kumar Rai The program fosters cross-collaboration through presentations, group discussions and a “CEO Challenge” set by Jim Lang, enabling #Innovation for our clients and ourselves. Our executive panelists, Jim, Faruk Capan, Gregory Skalicky, MBA, Faruk Abdullah and Boris Kushkuley, PhD, gave feedback and implementation advice. We also want to thank our external vendors and presenters, Matthew Meuleners, Louis Gerst, Dr. Nicole Price and KNOLSKAPE Simulations, for their facilitation. #Teamwork #WeAreEVERSANA #GrowTalent

Watch the full recording: https://lnkd.in/eGvBnkPk What type of deal activity do you expect to accelerate the most in 2024 and beyond? In our recent webinar, industry experts discussed the trends in deal activity for 2024 and beyond. Whether early-stage science or late-stage assets, companies are strategically navigating the market. Watch the full webinar to stay ahead of the game. #MandA #BDL #CommercialDueDiligence #IndustryInsights #Webinar James Stephanou, Calvin Fujimoto-Cassidy, Jeremy Snook, Faruk Abdullah, Andrew Therrien, Andrew Ying, CFA, MPH, Justin Averback, Kevin Yin, Srinivas Tapa, PhD, MBA, Xavier Aparicio

Watch the full recording: https://lnkd.in/eGvBnkPk What type of deal activity do you expect to accelerate the most in 2024 and beyond? In our recent webinar, industry experts discussed the trends in deal activity for 2024 and beyond. Whether it’s early-stage science or late-stage assets, companies are strategically navigating the market. Watch the full webinar to stay ahead of the game. #MandA #BDL #CommercialDueDiligence #IndustryInsights #Webinar James Stephanou, Calvin Fujimoto-Cassidy, Jeremy Snook